A new survey of 1,000 men aged over 40, commissioned by Eli Lilly and Company Limited (Lilly UK) as part of a new erectile dysfunction awareness campaign, 40over40, reveals that just over 10% of men in their early 40s are aware that ED strikes regularly in the fourth decade even though evidence suggests that 40% of men aged 40 or over have some form of ED.
New research has shown that 1 in 10 men experience erectile dysfunction (ED) and as many as 1 in 5 men suffer a loss of libido, as a result of work-related stress. These latest figures suggest that 90% of men have shown at least one clinical feature of stress due to work but only 54% of men know that stress from work may be the cause of their ED. Stress, either at work or home, is a known cause of ED and prolonged stress is associated with low testosterone levels.
Men treated for prostate cancer have high levels of psychological distress and many suffer ongoing sexual dysfunction and lower urinary tract symptoms, according to a survey of men in England designed to explore their supportive care needs. Prostate cancer is the commonest solid cancer in men, accounting for one in every four cancers diagnosed in males in England in 2004.
Men with erectile dysfunction should be examined for testosterone deficiency and the metabolic syndrome, because these conditions commonly occur together, a new study shows. The results will be presented at The Endocrine Society's 90th Annual Meeting in San Francisco."Erectile dysfunction is a portal into men's health," said the study's senior author, Aksam Yassin, MD, PhD, of the Clinic for Urology and Andrology of the Segeberger Clinics in Norderstedt, Germany.
UroToday.com - A group from the UK led by Bridget Candy report a meta-analysis in the BJU International on phosphodiesterase type 5 inhibitors (PDE5i) for the treatment of erectile dysfunction (ED) secondary to treatments for prostate cancer (CaP). Only randomized controlled trials were included and outcomes using validated scales such as the IIEF and SEP, successful sexual intercourse, time to effect, treatment satisfaction and health-related QOL were extracted.
Rexahn Pharmaceuticals, Inc. (AMEX:RNN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs, announced that the Company has initiated a Phase II clinical trial for its lead clinical compound ZoraxelTM, for the treatment of Erectile Dysfunction (ED). ZoraxelTM is being developed as an orally administered, on-demand-use tablet.
The U.S. Food and Drug Administration requested that SEI Pharmaceuticals, of Miami, Fla., recall all Xiadafil VIP Tabs sold in 8 tablet bottles (Lot # 6K029) or blister cards of 2 tablets (Lot # 6K029-SEI) because these products contain a potentially harmful, undeclared ingredient that may dangerously affect a person's blood pressure and can cause other life-threatening side effects. These lots of Xiadafil VIP Tabs bear an expiration date of September 2009 (09/09).
The U.S. Food and Drug Administration requested that SEI Pharmaceuticals, of Miami, Fla., recall all Xiadafil VIP Tabs sold in 8 tablet bottles (Lot # 6K029) or blister cards of 2 tablets (Lot # 6K029-SEI) because these products contain a potentially harmful, undeclared ingredient that may dangerously affect a person's blood pressure and can cause other life-threatening side effects. These lots of Xiadafil VIP Tabs bear an expiration date of September 2009 (09/09).
"Men with diabetes who are having trouble keeping an erection could be at increased risk of serious heart problems", BBC News reported. It said that a study has found that those with erectile dysfunction are twice as likely as other men with diabetes to develop heart disease. This finding could apparently be used to "alert both patients and healthcare providers to the future risk of coronary heart disease".
International experts from ten countries have teamed up to develop the first ever evidence-based definition of lifelong premature ejaculation (PE) in the hope that it will aid future diagnosis, treatment and research.
Next Page →